Want to see HK:1011 full AI Analyst Report?
China NT Pharma Group Co., Ltd. (1011) Ratios
China NT Pharma Group Co., Ltd. Ratios
HK:1011's free cash flow for Q2 2026 was $-14.35M. For the 2026 fiscal year, HK:1011's free cash flow was increased by $0.00 and operating cash flow was $-14.35M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.02 | 0.02 | 0.02 | 0.06 | 0.30 |
| Quick Ratio | 0.02 | 0.02 | 0.02 | 0.05 | 0.26 |
| Cash Ratio | 0.01 | 0.01 | 0.00 | 0.01 | 0.01 |
| Solvency Ratio | -0.04 | -0.07 | -0.21 | -0.04 | -0.09 |
| Operating Cash Flow Ratio | -0.04 | -0.01 | 0.08 | 0.03 | -0.15 |
| Short-Term Operating Cash Flow Coverage | -0.08 | -0.02 | 0.15 | 0.04 | -0.22 |
| Net Current Asset Value | $ -606.08M | $ -717.00M | $ -656.41M | $ -1.17B | $ -899.03M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.91 | 1.13 | 1.05 | 0.82 | 0.87 |
| Debt-to-Equity Ratio | -1.16 | -0.94 | -1.02 | -3.42 | -3.94 |
| Debt-to-Capital Ratio | 7.35 | -16.24 | 64.15 | 1.41 | 1.34 |
| Long-Term Debt-to-Capital Ratio | 0.00 | -0.02 | -0.01 | 0.00 | 111.38 |
| Financial Leverage Ratio | -1.27 | -0.84 | -0.97 | -4.16 | -4.52 |
| Debt Service Coverage Ratio | -0.03 | -0.02 | 0.00 | -0.00 | -0.03 |
| Interest Coverage Ratio | -0.46 | -0.42 | -1.95 | -0.67 | -1.12 |
| Debt to Market Cap | 0.70 | 5.61 | 0.79 | 5.47 | 0.76 |
| Interest Debt Per Share | 0.56 | 1.54 | 0.44 | 0.46 | 0.49 |
| Net Debt to EBITDA | -26.42 | -42.35 | 258.21 | 78.93 | -46.28 |
| Profitability Margins | |||||
| Gross Profit Margin | 39.78% | 13.86% | 100.00% | 60.50% | 64.16% |
| EBIT Margin | -51.18% | -34.84% | -61.78% | -5.15% | -26.48% |
| EBITDA Margin | -48.51% | -22.79% | 18.06% | 5.02% | -7.84% |
| Operating Profit Margin | -51.18% | -34.84% | -763.07% | -12.82% | -43.86% |
| Pretax Profit Margin | -108.68% | -140.89% | -453.01% | -24.16% | -65.62% |
| Net Profit Margin | -107.79% | -140.56% | -1949.36% | -32.07% | -65.96% |
| Continuous Operations Profit Margin | -108.68% | -140.56% | -454.67% | -24.16% | -66.76% |
| Net Income Per EBT | 99.18% | 99.77% | 430.31% | 132.70% | 100.53% |
| EBT Per EBIT | 212.35% | 404.36% | 59.37% | 188.53% | 149.60% |
| Return on Assets (ROA) | -7.49% | -15.97% | -43.63% | -6.60% | -15.65% |
| Return on Equity (ROE) | 9.51% | 13.37% | 42.29% | 27.48% | 70.75% |
| Return on Capital Employed (ROCE) | 4.51% | 3.38% | 16.73% | 16.19% | -167.43% |
| Return on Invested Capital (ROIC) | -28.83% | 56.99% | -1045.34% | -4.01% | -14.67% |
| Return on Tangible Assets | -7.49% | -15.97% | -43.65% | -7.84% | -18.82% |
| Earnings Yield | -5.73% | -79.67% | -32.78% | -44.00% | -13.69% |
| Efficiency Ratios | |||||
| Receivables Turnover | 7.62 | 25.96 | 0.73 | 6.15 | 18.21 |
| Payables Turnover | 5.46 | 65.66 | 0.00 | 9.65 | 1.82 |
| Inventory Turnover | 36.26 | 194.64 | 0.00 | 7.93 | 2.54 |
| Fixed Asset Turnover | 38.45 | 69.91 | 7.80 | 0.42 | 0.91 |
| Asset Turnover | 0.07 | 0.11 | 0.02 | 0.21 | 0.24 |
| Working Capital Turnover Ratio | -0.04 | -0.06 | -0.01 | -0.24 | -0.38 |
| Cash Conversion Cycle | -8.83 | 10.38 | 498.10 | 67.55 | -36.67 |
| Days of Sales Outstanding | 47.90 | 14.06 | 498.10 | 59.34 | 20.05 |
| Days of Inventory Outstanding | 10.07 | 1.88 | 0.00 | 46.04 | 143.79 |
| Days of Payables Outstanding | 66.79 | 5.56 | 0.00 | 37.82 | 200.52 |
| Operating Cycle | 57.97 | 15.94 | 498.10 | 105.37 | 163.84 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.04 | -0.03 | 0.06 | 0.02 | -0.07 |
| Free Cash Flow Per Share | -0.04 | -0.04 | 0.04 | 0.02 | -0.07 |
| Dividend Paid and CapEx Coverage Ratio | -158.51 | -50.93 | 3.91 | 8.06 | -208.63 |
| Capital Expenditure Coverage Ratio | -158.51 | -50.93 | 3.91 | 8.06 | -208.63 |
| Operating Cash Flow Coverage Ratio | -0.08 | -0.02 | 0.15 | 0.04 | -0.16 |
| Operating Cash Flow to Sales Ratio | -1.02 | -0.24 | 6.85 | 0.17 | -0.59 |
| Free Cash Flow Yield | -5.44% | -13.80% | 8.58% | 21.01% | -12.39% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -17.45 | -1.26 | -3.05 | -2.27 | -7.31 |
| Price-to-Sales (P/S) Ratio | 18.81 | 1.76 | 59.47 | 0.73 | 4.82 |
| Price-to-Book (P/B) Ratio | -1.66 | -0.17 | -1.29 | -0.62 | -5.17 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -18.39 | -7.24 | 11.66 | 4.76 | -8.07 |
| Price-to-Operating Cash Flow Ratio | -18.51 | -7.39 | 8.68 | 4.17 | -8.11 |
| Price-to-Earnings Growth (PEG) Ratio | 0.22 | -0.07 | -0.01 | 0.04 | 0.37 |
| Enterprise Value Multiple | -65.19 | -50.09 | 587.56 | 93.45 | -107.75 |
| Enterprise Value | 764.00M | 433.30M | 781.46M | 971.45M | 1.92B |
| EV to EBITDA | -65.19 | -50.09 | 587.56 | 93.45 | -107.75 |
| EV to Sales | 31.63 | 11.41 | 106.09 | 4.69 | 8.45 |
| EV to Free Cash Flow | -30.92 | -46.87 | 20.79 | 30.63 | -14.14 |
| EV to Operating Cash Flow | -31.12 | -47.79 | 15.48 | 26.83 | -14.21 |
| Tangible Book Value Per Share | -0.44 | -1.51 | -0.40 | -0.21 | -0.20 |
| Shareholders’ Equity Per Share | -0.44 | -1.51 | -0.40 | -0.13 | -0.11 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | -0.00 | -0.24 | -0.02 |
| Revenue Per Share | 0.04 | 0.14 | 0.01 | 0.11 | 0.12 |
| Net Income Per Share | -0.04 | -0.20 | -0.17 | -0.03 | -0.08 |
| Tax Burden | 0.99 | 1.00 | 4.30 | 1.33 | 1.01 |
| Interest Burden | 2.12 | 4.04 | 7.33 | 4.69 | 2.48 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.02 | 0.03 |
| SG&A to Revenue | 0.91 | 0.49 | 8.63 | 0.29 | 0.36 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.97 | 0.17 | -0.40 | -0.67 | 0.91 |
Currency in CNY